Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Celyad Sa ADR (CYAD)

Celyad Sa ADR (CYAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials FinancialNewsMedia - Thu Jan 19, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END

TCBP : 1.4600 (+0.69%)
TCBPW : 0.0178 (+18.67%)
CRDF : 3.52 (-21.43%)
CYAD : 0.4700 (-11.10%)
RIGL : 1.2000 (+4.35%)
AZN : 76.35 (+0.73%)
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction Business Wire - Tue Sep 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights Globe Newswire - Fri Aug 5, 2022

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r)...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial Globe Newswire - Mon Aug 1, 2022

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call Globe Newswire - Thu Jul 28, 2022

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Announces Leadership Updates Globe Newswire - Fri Jun 24, 2022

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) Globe Newswire - Tue May 31, 2022

MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know Zacks - Wed May 25, 2022

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CYAD : 0.4700 (-11.10%)
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference Globe Newswire - Tue May 17, 2022

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage...

CYAD : 0.4700 (-11.10%)
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights Globe Newswire - Thu May 5, 2022

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext...

CYAD : 0.4700 (-11.10%)

Barchart Exclusives

2 Uranium Stocks With 50% or More Upside Potential Barchart - Sat May 4, 8:15AM CDT
As U.S. passes the bill to ban uranium import from Russia, U.S. based uranium companies are sure to enjoy the increased demand. Here are 2 stocks with upside according to analysts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot